Sidoti Increases Earnings Estimates for Prenetics Global

Key Points

• Sidoti raised Prenetics Global’s Q1 2028 EPS estimate to $0.29 from $0.28 and projects FY2028 EPS of $2.12, while the current full-year consensus remains a loss of $1.28 per share.
• Prenetics reported a quarterly loss of $0.53 per share, beating estimates for a $0.64 loss, but revenue of $46.49 million fell short of the $49.02 million consensus. The company continued to post negative net margin and return on equity.
• Analyst sentiment is mixed but leans positive, with four Buy ratings and one Sell rating producing a “Moderate Buy” consensus and an average price target of $34.25; shares opened at $18.76.

Prenetics Global Limited (NASDAQ:PRE - Free Report) - Equities research analysts at Sidoti increased their Q1 2028 EPS estimates for shares of Prenetics Global in a research report issued to clients and investors on Wednesday, August 19th. Sidoti analyst A. Hantman now expects that the company will post earnings of $0.29 per share for the quarter, up from their previous estimate of $0.28. The consensus estimate for Prenetics Global's current full-year earnings is ($1.28) per share. Sidoti also issued estimates for Prenetics Global's FY2028 earnings at $2.12 EPS.

Several other equities analysts also recently issued reports on PRE. Wall Street Zen downgraded shares of Prenetics Global from a "hold" rating to a "sell" rating in a research note on Saturday, July 25th. Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Prenetics Global in a research note on Friday, July 17th. Finally, Benchmark boosted their price target on Prenetics Global from $30.00 to $40.00 and gave the company a "buy" rating in a report on Wednesday, July 15th. Four investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of "Moderate Buy" and an average target price of $34.25.

Prenetics Global Price Performance

Shares of NASDAQ PRE opened at $18.76 on Thursday. The company has a 50-day simple moving average of $19.13 and a 200-day simple moving average of $18.88. The company has a market cap of $316.48 million, a PE ratio of -4.51 and a beta of 0.26. Prenetics Global has a 12 month low of $7.18 and a 12 month high of $23.63.

Prenetics Global (NASDAQ:PRE - Get Free Report) last released its earnings results on Tuesday, August 18th. The company reported ($0.53) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.64) by $0.11. Prenetics Global had a negative net margin of 47.43% and a negative return on equity of 19.46%. The company had revenue of $46.49 million for the quarter, compared to analyst estimates of $49.02 million.

Institutional Investors Weigh In On Prenetics Global

A number of institutional investors have recently bought and sold shares of the stock. State of Wyoming acquired a new position in Prenetics Global during the first quarter worth approximately $48,000. Wells Fargo & Company MN purchased a new stake in shares of Prenetics Global during the 4th quarter valued at $47,000. JPMorgan Chase & Co. acquired a new stake in shares of Prenetics Global during the 3rd quarter worth $65,000. Manatuck Hill Partners LLC acquired a new stake in shares of Prenetics Global during the 4th quarter worth $170,000. Finally, T3 Companies LLC purchased a new position in shares of Prenetics Global in the 4th quarter worth $170,000. 25.01% of the stock is currently owned by hedge funds and other institutional investors.

Prenetics Global Company Profile

Prenetics Global NASDAQ: PRE is a molecular diagnostics and genetic testing company that delivers a broad range of laboratory and at-home testing solutions. The company's core offerings include next-generation sequencing (NGS) panels for hereditary health risks, pharmacogenomic reports to guide medication choices, and comprehensive consumer DNA testing services. In addition to genetic insights, Prenetics provides infectious disease diagnostics—most notably real-time PCR testing for pathogens such as SARS-CoV-2—through an integrated platform that combines sample collection, laboratory processing and digital reporting.

Serving both business-to-consumer and business-to-business markets, Prenetics operates a network of laboratories and service centers across Asia Pacific, Europe, the Middle East and North America.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source